Beida Pharmaceutical: Clinical Trial Applications for Combination Use of BPI-572270 Capsules Accepted

36Kr learned from a Beida Pharmaceutical announcement that clinical trial applications for BPI-572270 capsules, filed by its wholly owned subsidiary Hangzhou Jingyao Biotechnology Co., Ltd., have been accepted by the National Medical Products Administration. The applications cover combinations with chemotherapy, PD-1/VEGF bispecific antibodies, PD-1 monoclonal antibodies plus platinum-based chemotherapy, FAK inhibitors, EGFR antibodies and other treatment regimens.